Evidence map›Paper›PMID 41341085›Full record

ArticleProceedings (Baylor University. Medical Center)2025

BRAF inhibitor-induced necrotizing granulomatous lymphadenopathy: a case report of drug-induced sarcoid-like reaction.

Seena Firouzbakht, Ali Rizvi, Ariane Mosher, Samya Yaqub, Mark Sigler

Abstract readCase Reports
In one paragraph

Article in Proceedings (Baylor University. Medical Center), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Seena FirouzbakhtDepartment of Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.
Ali RizviDepartment of Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.ORCID https://orcid.org/0009-0006-3285-0861
Ariane MosherDepartment of Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.
Samya YaqubDepartment of Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.
Mark SiglerDepartment of Internal Medicine, Texas Tech University Health Sciences Center, Amarillo, Texas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRAF inhibitors are a class of targeted therapies used in the treatment of malignant melanoma. They are the standard of care in the treatment of advanced BRAF-mutated malignant melanoma and are generally well tolerated. However, in rare cases, an adverse effect involving granulomatous lymphadenopathy may occur. This case report discusses a patient receiving BRAF inhibitor therapy who developed mediastinal lymphadenopathy with necrotizing granulomatous disease found on intranodal forceps biopsy.

Indexed as

BRAF inhibitorsdrug-induced sarcoid-like reactiongranulomatous lymphadenopathy

Identifiers

PMID41341085
PMCPMC12671502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.